title: Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog.
abstract: OBJECTIVE
  In the current study we have profiled a range of compounds at alpha 1 adrenoceptor subtypes in vitro and have assessed their effects in vivo using the anesthetized dog in an attempt to elucidate the predominant alpha 1 adrenoceptor subtype mediating contractile responses of the canine prostate.
  
  
  METHODS
  The affinity of compounds for alpha 1 adrenoceptor subtypes was determined by displacement of [3H] prazosin binding from stably transfected rat 1 fibroblasts expressing alpha 1A, alpha 1B, and alpha 1C, adrenoceptor subtypes. The potency of these agents was then assessed in vivo using an anesthetized dog model allowing simultaneous measurement of prostatic pressure and blood pressure following intravenous (i.v.) administration of phenylephrine (1 to 128 micrograms/kg).
  
  
  RESULTS
  All compounds examined in this study showed high and similar affinity for alpha 1 adrenoceptor subtypes, with the exception of 5-Methyl-urapidil, which was selective for alpha 1C (pKi = 9.3) over alpha 1B (pKi = 7.2) and alpha 1A (pKi = 8.1). Doxazosin, terazosin, alfuzosin, and tamsulosin were potent antagonists of phenylephrine responses and in vivo derived "pseudo pA2" determinations showed that the drugs did not discriminate between prostatic and vascular receptors. 5-Methyl-urapidil was also a potent antagonist of phenylephrine-induced responses but was selective for prostatic pressure ("pseudo pA2" = 8.7) over blood pressure ("pseudo pA2" = 7.2).
  
  
  CONCLUSIONS
  Data in the present study suggest a predominant role of the alpha 1C adrenoceptor subtype in the contractile response of the canine prostate to phenylephrine in vivo. This model therefore provides a suitable means of assessing putative prostate-selective antagonists for the treatment of benign prostatic hyperplasia.
authors.affiliation: Department of Discovery Biology, Pfizer Central Research, Sandwich, Kent, United Kingdom.
authors.forename: B A
authors.initials: BA
authors.lastname: Kenny
authors.forename: A M
authors.initials: AM
authors.lastname: Naylor
authors.forename: A J
authors.initials: AJ
authors.lastname: Carter
authors.forename: A M
authors.initials: AM
authors.lastname: Read
authors.forename: P M
authors.initials: PM
authors.lastname: Greengrass
authors.forename: M G
authors.initials: MG
authors.lastname: Wyllie
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000345:Affinity Labels; D000770:Anesthesia, Endotracheal; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D017292:Doxazosin / Q000494:pharmacology; D008297:Male; D008954:Models, Biological; D010656:Phenylephrine / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011224:Prazosin / Q000031:analogs & derivatives / Q000494:pharmacology; D011312:Pressure; D011467:Prostate / Q000187:drug effects* / Q000502:physiology; D011799:Quinazolines / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D000077409:Tamsulosin
chemical_list: D000317:Adrenergic alpha-Antagonists; D000345:Affinity Labels; D010879:Piperazines; D011799:Quinazolines; D013449:Sulfonamides; C057446:5-methylurapidil; D010656:Phenylephrine; C041226:Terazosin; C047638:alfuzosin; D000077409:Tamsulosin; D017292:Doxazosin; D011224:Prazosin